Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Suzhou Ribo Life Science CoHKSE:06938 -4.07%9 Days Payable is 427.61 as of Dec. 2025, which is 42% below its 10-year median of 736.82. GuruFocus rates HKSE:06938 with a GF Score™ of 9/100. The stock has 2 warning signs investors should review. Among 708 Biotechnology companies, Suzhou Ribo Life Science Co ranks better than 68.5% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:06938 vs VRTX, REGN, MRNA: Days Payable Comparison
For the Biotechnology subindustry, Suzhou Ribo Life Science Co's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Suzhou Ribo Life Science Co Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Suzhou Ribo Life Science Co's Days Payable distribution charts can be found below:
* The bar in red indicates where Suzhou Ribo Life Science Co's Days Payable falls into.
Suzhou Ribo Life Science Co Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Suzhou Ribo Life Science Co (HKSE:06938) has a Days Payable of 427.61 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Suzhou Ribo Life Science Co and its competitors. This is 42% below median its historical median of 736.82. Over the past decade, Suzhou Ribo Life Science Co's Days Payable has ranged from 256.60 to 357,236.73. According to the industry distribution chart, Suzhou Ribo Life Science Co ranks #223 out of 708 companies in the Biotechnology industry, placing it in the top 31.5%.
Is Suzhou Ribo Life Science Co's Days Payable too high?
Suzhou Ribo Life Science Co's current Days Payable of 427.61 is 42% below median its 10-year median of 736.82. Over the past 10 years, this metric has ranged from a low of 256.60 to a high of 357,236.73. The Biotechnology industry median Days Payable is 111.42. Suzhou Ribo Life Science Co's value of 427.61 is 283.8% above this industry median. Based on the distribution chart, Suzhou Ribo Life Science Co ranks #223 out of 708 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Suzhou Ribo Life Science Co has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Suzhou Ribo Life Science Co's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Suzhou Ribo Life Science Co ranks #223 out of 708 companies for Days Payable. This puts Suzhou Ribo Life Science Co in the upper half of its industry. The industry median Days Payable is 111.42. Suzhou Ribo Life Science Co's value of 427.61 is 283.8% above this benchmark. Historically, Suzhou Ribo Life Science Co's own Days Payable has ranged from 256.60 to 357,236.73 over the past decade. While the company's 10-year median is 736.82 vs. the industry median of 111.42, Suzhou Ribo Life Science Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 111.42, based on 708 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Suzhou Ribo Life Science Co's current Days Payable of 427.61 is 283.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Suzhou Ribo Life Science Co and its competitors. For the Biotechnology industry, the median Days Payable is 111.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Suzhou Ribo Life Science Co's current Days Payable is 427.61, which is 42% below median its own 10-year median of 736.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Suzhou Ribo Life Science Co stock overvalued right now?
Suzhou Ribo Life Science Co (HKSE:06938) has a current Days Payable of 427.61. The current Days Payable is 427.61, which is 42% below median its 10-year median of 736.82 and 283.8% above the Biotechnology industry median of 111.42. Suzhou Ribo Life Science Co's overall GF Score™ is 9/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Suzhou Ribo Life Science Co (HKSE:06938), the current Days Payable is 427.61 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Suzhou Ribo Life Science Co Ltd is a biopharmaceutical company engaged in oligonucleotide R&D, with a focus on siRNA therapeutics. The company's pipeline focuses on cardiovascular, metabolic, renal and liver diseases. Its pipeline includes RBD4059, RBD5044, RBD7007, RBD1119, RBD3103, SR122, SR126, RBD1016, SR112/SR113, among others. It has one reportable operating segment.
9GF Score
Get the complete analysis for HKSE:06938
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:06938 has been successfully added to your 
